Screener
United Therapeutics UTHR EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from United Therapeutics’s reported figures.
The source filing: United Therapeutics’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 6:31 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001082554-26-000027
FAQ
- What is United Therapeutics's EBITDA?
- United Therapeutics (UTHR) reported EBITDA of $355M in Q2 2026.
- How has United Therapeutics's EBITDA changed year-over-year?
- United Therapeutics's EBITDA decreased by 7.9% year-over-year, from $385.6M to $355M.
- What is the long-term trend for United Therapeutics's EBITDA?
- Over 4 years (2021 to 2025), United Therapeutics's EBITDA has grown at a 27.0% compound annual growth rate (CAGR), from $605.8M to $1.58B.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about United Therapeutics's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude